Patents/Assignees

Alnylam Pharmaceuticals, Inc.

82 patents in portfolio

US12397013utility2025
Extrahepatic Delivery
0 cites
US12385043utility2025
Modified Double-stranded RNA Agents
0 cites
US12385044utility2025
Modified Double-stranded RNA Agents
0 cites
US12378553utility2025
Modified Double-stranded RNA Agents
0 cites
US12364762utility2025
Biodegradable Lipids for the Delivery of Active Agents
0 cites
US12365896utility2025
Complement Component C3 Irna Compositions and Methods of Use Thereof
0 cites
US12350338utility2025
Biodegradable Lipids for the Delivery of Active Agents
0 cites
US12343398utility2025
Biodegradable Lipids for the Delivery of Active Agents
0 cites
US12338439utility2025
Factor XII (hageman Factor) (F12), Kallikrein B, Plasma (fletcher Factor) 1 (KLKB1), and Kininogen 1 (KNG1) Irna Compositions and Methods of Use Thereof
0 cites
US12331297utility2025
Coagulation Factor V (F5) Irna Compositions and Methods of Use Thereof
0 cites
US12290573utility2025
Modified Rnai Agents
0 cites
US12275938utility2025
Modified RNA Agents with Reduced Off-target Effect
0 cites
US12258565utility2025
Complement Component C3 Irna Compositions and Methods of Use Thereof
0 cites
US12247203utility2025
Modified RNA Agents with Reduced Off-target Effect
0 cites
US12239709utility2025
Biodegradable Lipids for the Delivery of Active Agents
0 cites
US12241064utility2025
REVERSIR™ Compounds
0 cites
US12227744utility2025
Compositions and Methods for Inhibiting Expression of Transthyretin
0 cites
US12221607utility2025
Multi-targeted Single Entity Conjugates
0 cites
US12173287utility2024
Compositions and Methods for Improving Strand Biased
0 cites
US12173288utility2024
Oligonucleotide-ligand Conjugates and Process for Their Preparation
0 cites

← PreviousPage 2 of 5Next →